Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Cash & Equivalents (2016 - 2025)

CorMedix (CRMD) has disclosed Cash & Equivalents for 14 consecutive years, with $144.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 256.29% to $144.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $144.8 million through Dec 2025, up 256.29% year-over-year, with the annual reading at $144.8 million for FY2025, 256.29% up from the prior year.
  • Cash & Equivalents hit $144.8 million in Q4 2025 for CorMedix, up from $48.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $159.3 million in Q2 2025 to a low of $19.7 million in Q2 2023.
  • Historically, Cash & Equivalents has averaged $55.7 million across 5 years, with a median of $43.3 million in 2022.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 599.08% in 2021 and later crashed 70.38% in 2022.
  • Year by year, Cash & Equivalents stood at $53.3 million in 2021, then fell by 19.07% to $43.1 million in 2022, then grew by 23.56% to $53.3 million in 2023, then fell by 23.75% to $40.7 million in 2024, then skyrocketed by 256.29% to $144.8 million in 2025.
  • Business Quant data shows Cash & Equivalents for CRMD at $144.8 million in Q4 2025, $48.5 million in Q3 2025, and $159.3 million in Q2 2025.